Femme

Femme is a probiotic complex by SynBalance, specifically designed to support women’s intimate health.
Femme has been clinically tested to confirm the effectiveness in humans. The first clinical trial has investigated the ability of probiotic strains to colonize and persist in the vagina through oral intake. In a RDBPC trial 40 healthy women were enrolled and asked to take either Femme, 3B CFU/day or placebo for 14 days. PCR results related to the treatment and the follow-up periods, have demonstrated that Femme strains can reach the vagina from the gastrointestinal tract, colonize and persist (p<0,05). Femme has been further investigated to evaluate the reduction of relapses in women with BV: 75 women suffering from bacterial vaginosis were enrolled and treated with antibiotic for 5 days. Next, volunteers have been split into two groups: 50 women continued with probiotic intake (3B CFU per day) for 14 days after antibiotic treatment plus 7 days per month for the following 4 months, while the last 25 were monitored as control group without probiotic intake. Results demonstrated that the recurrence rate dropped at 16% in active group with respect to 40% of control group (p<0,01), in line with epidemiological data (40-60%). Additionally, the active group reported to perceive an improvement of the clinical markers associated to BV.
The last clinical trial performed aimed at investigating the role of probiotic ingredients in modulating the vaginal microbiota in menopausal women observing after just one month a higher abundance of Lactobacilli species as well as improvement of vaginal well-being.